Conditions: Lupus Erythematosus, Systemic
Keywords: Atacicept Placebo
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 306
Healthy volunteers: no

Brief summary:
This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: Atacicept 75 milligram (mg) intervention 2: Atacicept 150 mg intervention 3: Placebo
Intervention descriptions: intervention 1: Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks. intervention 2: Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks. intervention 3: Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.

Protocol document: